A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries a risk of bleeding and infection. Findings from this research may offer a more accurate and reliable method to diagnose prostate cancer.
“This study is exciting because it has the potential to offer a non-invasive alternative to the traditional PSA test in order to diagnose significant prostate cancers,” said Craig Rogers, M.D., chair of the Vattikuti Urology Institute at Henry Ford Health System. “The discovery of new biomarkers ultimately benefits our patients, as it advances our understanding of this complex disease and how to most effectively treat it.”
When the KLK4 protein coding gene and KLKP1 pseudogene fuse together, the fusion gene KLK4-KLKP1 is formed. Pseudogenes like KLKP1 are the non-functional, or dead, versions of an actual gene that is normally not expressed in a cell but can become active in cancerous cells and disrupt the functions of the actual gene.
“The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30 percent of high Gleason grade prostate cancer,” said Dr. Palanisamy. “Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target.”
The researchers conducting this study screened a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients of other races), which revealed that the KLK4-KLKP1 fusion gene is expressed in about 32 percent of prostate cancer patients, representing a distinct subset of prostate cancer cases. Correlative analysis showed that the new fusion gene can be used in combination with other prostate cancer molecular markers for cancer detection. In addition to urine samples, the fusion could also be detected in needle biopsy tissue samples by using a specific antibody.
Prostate cancer is the most common cancer among men in the United States. Advances in diagnosis, treatment, and management have resulted in increased survival rates, yet prostate cancer still remains the second leading cause of cancer-related deaths among American men. One of the major barriers to achieving successful prostate cancer control is the underlying molecular complexity of the disease itself.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- A Call to Test Men With Prostate Cancer for COVID-19on August 7, 2020 at 8:14 am
A team of New York City urologists proposes that men with prostate cancer get tested for COVID-19 because of their vulnerabilities to the infection.
- Beyond PSA: New Prostate Cancer Screening Optionson August 7, 2020 at 7:42 am
In the wake of more than a decade of controversy over PSA testing, research is emerging that points to new approaches for the stratification of prostate cancer risk. Two noninvasive tests — an ...
- NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403on August 7, 2020 at 6:35 am
Cancer Targeted Technology receives $1.44M in year 2 of SBIR Phase IIB grant to fund clinical trial of new PSMA-targeted therapeutic agent, CTT1403.
- Dr. Roach: Active surveillance is today’s approach to some prostate canceron August 6, 2020 at 9:03 pm
It came from the observation that a lot of prostate cancer behaved very indolently. Years could go by without the cancer causing problems. Since prostate cancer treatment, mostly surgery, risked the ...
- What Young Guys Should Do Now to Prevent Prostate Cancer Lateron August 6, 2020 at 11:45 am
While prostate cancer strikes one in nine men at some point in their lifetimes, guys don't usually think about it until later in life. Now's a good time to not be "usual." Taking these steps now can ...
- An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer riskon August 6, 2020 at 2:18 am
Genome wide association studies have identified multiple loci associated with risk of developing prostate cancer but the functional significance of many of these are unknown. Here, after generating ...
- Haptoglobin polymorphism and prostate cancer mortalityon August 4, 2020 at 2:19 am
Prostate cancer is a common malignancy in men worldwide and it is known that oxidative stress is a risk factor for cancer development. A common functional haptoglobin (Hp) polymorphism, originating ...
- Darolutamide in prostate cancer: Indication of considerable added benefiton August 3, 2020 at 9:29 am
Up to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy ...
- Fewer Cancer Visits; More Breast Cancer, Younger Women; Diet and Prostate Canceron July 30, 2020 at 10:55 pm
AstraZeneca and Daiichi Sankyo entered into a second multibillion dollar oncology agreement in as many years, this time to develop an antibody-drug conjugate cancer therapy targeting TROP-2. ( Reuters ...
- New blood test can detect prostate cancer and confirm the stage of the diseaseon July 30, 2020 at 12:52 am
A new blood test developed by scientists and clinicians is able to detect the presence of prostate cancer and confirm how advanced it is.
via Bing News